Clik here to view.
Novocure Announces Optune Now Available at more than 200 Leading Cancer...
NEW YORK Novocure announced today that more than 200 treatment centers in the United States have been certified to prescribe Optune to patients with recurrent glioblastoma (GBM). GBM is the most...
View ArticleClik here to view.
AstraZeneca Presents Further Evidence for the Potential of AZD9291 in...
LONDON AstraZeneca today announced updated data on AZD9291 in first-line patients with epidermal growth factor receptor mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC) and...
View ArticleClik here to view.
Chugai’s ALK Inhibitor “Alectinib,” New Drug Application Submitted for ALK...
TOKYO Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO:...
View ArticleClik here to view.
U.S. FDA Grants Priority Review to Takeda’s Ixazomib for Patients with...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New...
View ArticleClik here to view.
Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo®) in the UK by...
TOKYO & LUGANO, Switzerland Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman and CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and a wholly owned subsidiary of Chugai, Chugai...
View ArticleClik here to view.
武田公司用于复发/难治多发性骨髓瘤患者的 ixazomib列入美国FDA优先评审
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE: 4502)今天宣布，ixazomib已列入美国食品药品管理局(FDA)的新药申请(NDA)优先评审，ixazomib是首个口服蛋白酶体抑制剂类研究药物，用于治疗复发和/或难治多发性骨髓瘤患者。 武田法规事务副总裁Melody Brown表示：“美国和欧洲的监管部门都认定，ixazomib...
View ArticleClik here to view.
Gencia and Takeda Team to Discover and Develop Novel Class of Mitochondrial...
CHARLOTTESVILLE, Va. & OSAKA, Japan Gencia LLC and Takeda Pharmaceutical Company Limited announced today a partnership to develop a new class of small molecule drugs as potential treatments for...
View ArticleClik here to view.
Jubilant DraxImage Signs Term Sheet with Cyclopharm for Exclusive License to...
MONTREAL & SYDNEY Jubilant DraxImage Inc. (“DraxImage”) and Cyclopharm Limited (“CYC”) are pleased to announce the signing of a term sheet, subject to satisfactory due diligence and execution of...
View ArticleClik here to view.
VPS Healthcare第三届国际肿瘤会议吸引900多位代表与会
阿拉伯联合酋长国阿布扎比 (美国商业资讯)–综合性医疗保健提供商VPS Healthcare召开了其第三届国际肿瘤会议，会议主题是“通过早期检测和预防为癌症治疗导航”。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿： http://www.businesswire.com/news/home/20150914005450/zh-CN/ VPS...
View ArticleClik here to view.
米FDA、再発性／難治性多発性骨髄腫患者に対する武田薬品のイキサゾミブに優先審査の指定を与える
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ）– 武田薬品工業株式会社（TSE: 4502）は本日、米食品医薬品局（FDA）がイキサゾミブの新薬承認申請（NDA）に優先審査の指定を与えたと発表しました。イキサゾミブは再発性もしくは難治性または両方の多発性骨髄腫を抱える患者の治療を目的とする初の経口プロテアソーム阻害薬としての治験薬です。...
View ArticleClik here to view.
VPSヘルスケアの第3回国際腫瘍学大会に900人以上の代表が出席
アラブ首長国連邦アブダビ （ビジネスワイヤ） — 統合型ヘルスケアプロバイダーのVPSヘルスケアは、「早期発見と早期予防でがん治療のかじ取りをする」というテーマで第3回国際腫瘍学大会を開会しました。 このSmart News Release（スマート・ニュース・リリース）にはマルチメディアのコンテンツが含まれています。リリース全文はこちらから：...
View ArticleClik here to view.
Jubilant DraxImage与 Cyclopharm签署排他性授权条款清单，在美国推广Technegas
蒙特利尔和悉尼 — (美国商业资讯) — Jubilant DraxImage Inc. (“DraxImage”)与Cyclopharm Limited (“CYC”)欣然宣布签署一份条款清单，DraxImage获得在美国推广和分销Technegas 的排他性授权，该清单有待确定性协议得到满意的尽职调查和执行，以及其他必要的审批。DraxImage将协助CYC开展...
View ArticleClik here to view.
Jubilant DraxImage、米国でTechnegasを上市するための独占的ライセンスの条件規定書をCyclopharmと取り交わす
モントリオール & シドニー — （ビジネスワイヤ） — Jubilant DraxImage Inc.（以下「DraxImage」）とCyclopharm...
View ArticleClik here to view.
美国癌症协会转用Rimini Street的支持服务，将节省的开支用于拯救生命
拉斯维加斯 (美国商业资讯)–SAP SEs (NYSE: SAP) Business Suite和BusinessObjects软件以及甲骨文公司 (NYSE: ORCL) Siebel、PeopleSoft、JD Edwards、E-Business Suite、Oracle Database、Oracle Middleware、Hyperion和Oracle...
View ArticleClik here to view.
Cell Signaling Technology宣布发布首款上市的IHC核准的VISTA抗体
纽约 (美国商业资讯)–全球性抗体提供商Cell Signaling Technology, Inc. (CST)今天宣布发布用于生物医学研究的首款上市的IHC核准的人类特异性VISTA兔单克隆抗体(mAb)。该消息是在CRI-CIMT-EATI-AACR 首届国际癌症免疫疗法会议上宣布的，此次会议于2015年9月16-19日在纽约州纽约市召开，主题是将科学转化为生存。 VISTA（...
View ArticleClik here to view.
Clik here to view.
MerLion’s Finafloxacin Shown to be More Efficacious than Ciprofloxacin in the...
SINGAPORE MerLion Pharmaceuticals (“MerLion”) today presented detailed data from its Phase 2 study in patients hospitalized with complicated urinary tract infections (cUTI) and pyelonephritis...
View ArticleClik here to view.
NovoCure Limited Announces Launch of Initial Public Offering
ST. HELIER, Jersey NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares...
View ArticleClik here to view.
Clik here to view.
Takeda to Highlight Ixazomib Clinical Development Program at Upcoming...
ROME Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming 15th...
View Article